Q5119 HCPCS code: Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg
Q5119 is the HCPCS Level II code for injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg. In 2024 Medicare paid an average of $15.83 per service for Q5119 across 1,648,407 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 150 per day on outpatient hospital claims. Medicare volume fell 42% from 2022 to 2024 (2,851,296 to 1,648,407 services). In 2024, about 3,044 clinicians billed Medicare for Q5119 for 6,139 beneficiaries; California, Texas, Florida accounted for 34% of services.
Code details
| Field | Value |
|---|---|
| Section | Q codes — Temporary codes |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1D — Chemotherapy |
| Added | 2020-07-01 |
| Last action effective | 2020-07-01 |
Who bills Q5119 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 3,044 |
| Medicare beneficiaries | 6,139 |
| States with claims | 38 |
| Share of services in top 3 states (California, Texas, Florida) | 34% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for Q5119, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 2,851,296 | 9,809 | $46.29 | $36.98 |
| 2023 | 2,514,291 | 9,121 | $27.66 | $22.02 |
| 2024 | 1,648,407 | 6,139 | $19.89 | $15.83 |
States with the most Q5119 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| California | 209,457 | $15.88 |
| Texas | 209,124 | $15.85 |
| Florida | 137,819 | $15.73 |
| Illinois | 131,205 | $15.94 |
| Virginia | 109,120 | $16.00 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 150 | Prescribing Information |
| practitioner claims | 150 | Prescribing Information |
Medicare policy articles for this code
- A55639: Billing and Coding: Chemotherapy Agents for Non-Oncologic Conditions (WPS Insurance Corporation (MAC - Part A, MAC - Part B))
- A56380: Billing and Coding: Rituximab (Palmetto GBA (MAC - Part A, MAC - Part B))
- A58582: Billing and Coding: Off-label Use of Rituximab and Rituximab Biosimilars (CGS Administrators, LLC (MAC - Part A, MAC - Part B))
- A59101: Billing and Coding: Off-label Use of Rituximab and Rituximab Biosimilars (Wellpoint Federal (MAC - Part A, MAC - Part B))
Covered diagnoses (1,052 ICD-10-CM codes)
The diagnoses most often listed as covered in the policy articles above:
| ICD-10-CM | Diagnosis | Articles listing it |
|---|---|---|
| D59.0 | Drug-induced autoimmune hemolytic anemia | 4 |
| D59.11 | Warm autoimmune hemolytic anemia | 4 |
| D59.12 | Cold autoimmune hemolytic anemia | 4 |
| D59.13 | Mixed type autoimmune hemolytic anemia | 4 |
| D69.3 | Immune thrombocytopenic purpura | 4 |
| D69.41 | Evans syndrome | 4 |
| D89.811 | Chronic graft-versus-host disease | 4 |
| G35.A | Relapsing-remitting multiple sclerosis | 4 |
| G36.0 | Neuromyelitis optica [Devic] | 4 |
| G70.00 | Myasthenia gravis without (acute) exacerbation | 4 |
Showing 10 of 1,052. The full list, non-covered diagnoses and CSV export are in Caduvo.
What changed for Q5119
- 2020-07-01: Q5119 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code Q5119?
Q5119 is the HCPCS Level II code for injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg. Short descriptor: "Inj ruxience, 10 mg".
How much does Medicare pay for Q5119?
In 2024, the average Medicare payment was $15.83 per service (average allowed $19.89).
Does Medicare cover Q5119?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Which diagnoses support coverage for Q5119?
Medicare policy articles that cite Q5119 list 1,052 covered ICD-10-CM diagnosis codes across 4 articles. The most cited include D59.0 (Drug-induced autoimmune hemolytic anemia), D59.11 (Warm autoimmune hemolytic anemia), D59.12 (Cold autoimmune hemolytic anemia). A listed diagnosis is necessary but not sufficient; the policy's other criteria still apply.
How many units of Q5119 can be billed per day?
150 on outpatient hospital claims; 150 on practitioner claims (NCCI medically unlikely edits).
Related Q51 codes
- Q5100 — Injection, ustekinumab-kfce (yesintek), biosimilar, 1 mg
- Q5101 — Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram
- Q5102 — Injection, infliximab, biosimilar, 10 mg
- Q5103 — Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg
- Q5104 — Injection, infliximab-abda, biosimilar, (renflexis), 10 mg
- Q5105 — Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units
- Q5106 — Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units
- Q5107 — Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg
- Q5108 — Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg
- Q5109 — Injection, infliximab-qbtx, biosimilar, (ixifi), 10 mg
- Q5110 — Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
- Q5111 — Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under Q5119
- Watch Q5119 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for Q5119
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.